To monitor the activation status of DCs in KPC1242 tumors, the expression of CD86 on CD103+ or CD11b+ subsets of tumor resident MHC Class II+, CD11c+, Ly6C−, and CD64− DCs was quantified. The gene discussed is CD86; the disease is neoplasm.